Sabina Pozzi

Dr. Sabina Pozzi

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in Science Advances
Verified
Journal Article
Open access
LNLena Neufeld
Lena Neufeld
EYEilam Yeini
Eilam Yeini
NRNoa Reisman
Noa Reisman
YSYael Shtilerman
Yael Shtilerman
DBDikla Ben-Shushan
Dikla Ben-Shushan
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro
A perfusable vascularized 3D-bioprinted cancer model with stromal cells can be used for personalized therapy and target discovery.

24 October 2022 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
LNLena Neufeld
Lena Neufeld
EYEilam Yeini
Eilam Yeini
Sabina PozziSabina Pozzi
Sabina Pozzi
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro

26 March 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
EYEilam Yeini
Eilam Yeini
POPaula Ofek
Paula Ofek
Sabina PozziSabina Pozzi
Sabina Pozzi
NANitzan Albeck
Nitzan Albeck
DBDikla Ben-Shushan
Dikla Ben-Shushan
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro
Glioblastoma (GB) is a highly invasive type of brain cancer exhibiting poor prognosis. As such, its microenvironment plays a crucial role in its progression. Among the brain stromal cells, the microglia were shown to facilitate GB invasion and immunosuppression. However, the reciprocal mechanisms by which GB cells alter microglia/macrophages behavior are not fully understood. We propose that these mechanisms involve adhesion molecules such as the Selectins family. These proteins are involved in immune modulation and cancer immunity. We show that P-selectin mediates microglia-enhanced GB proliferation and invasion by altering microglia/macrophages activation state. We demonstrate these findings by pharmacological and molecular inhibition of P-selectin which leads to reduced tumor growth and increased survival in GB mouse models. Our work sheds light on tumor-associated microglia/macrophage function and the mechanisms by which GB cells suppress the immune system and invade the brain, paving the way to exploit P-selectin as a target for GB therapy.

1 August 2021 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
Sabina PozziSabina Pozzi
Sabina Pozzi
ASAnna Scomparin
Anna Scomparin
SDSahar Israeli Dangoor
Sahar Israeli Dangoor
DADaniel Rodriguez Ajamil
Daniel Rodriguez Ajamil
POPaula Ofek
Paula Ofek
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro

8 September 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
Sabina PozziSabina Pozzi
Sabina Pozzi
ASAnna Scomparin
Anna Scomparin
DBDikla Ben-Shushan
Dikla Ben-Shushan
EYEilam Yeini
Eilam Yeini
POPaula Ofek
Paula Ofek
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro
Development of resistance to chemo- and immunotherapies often occurs following treatment of melanoma brain metastasis (MBM). The brain microenvironment (BME), particularly astrocytes, cooperate toward MBM progression by upregulating secreted factors, among which we found that monocyte chemoattractant protein-1 (MCP-1) and its receptors, CCR2 and CCR4, were overexpressed in MBM compared with primary lesions. Among other sources of MCP-1 in the brain, we show that melanoma cells altered astrocyte secretome and evoked MCP-1 expression and secretion, which in turn induced CCR2 expression in melanoma cells, enhancing in vitro tumorigenic properties, such as proliferation, migration, and invasion of melanoma cells. In vivo pharmacological blockade of MCP-1 or molecular knockout of CCR2/CCR4 increased the infiltration of cytotoxic CD8 + T cells and attenuated the immunosuppressive phenotype of the BME as shown by decreased infiltration of Tregs and tumor-associated macrophages/microglia in several models of intracranially injected MBM. These in vivo strategies led to decreased MBM outgrowth and prolonged the overall survival of the mice. Our findings highlight the therapeutic potential of inhibiting interactions between BME and melanoma cells for the treatment of this disease.

13 December 2024 in Science Advances
Verified
Journal Article
Open access
SKShani Koshrovski-Michael
Shani Koshrovski-Michael
DADaniel Rodriguez Ajamil
Daniel Rodriguez Ajamil
PDPradip Dey
Pradip Dey
RKRon Kleiner
Ron Kleiner
STShahar Tevet
Shahar Tevet
RSRonit Satchi-Fainaro
Ronit Satchi-Fainaro
Combined therapies in cancer treatment aim to enhance antitumor activity. However, delivering multiple small molecules imposes challenges, as different drugs have distinct pharmacokinetic profiles and tumor penetration abilities, affecting their therapeutic efficacy. To circumvent this, poly(lactic-co-glycolic acid) (PLGA)–polyethylene glycol (PEG)–based nanoparticles were developed as a platform for the codelivery of synergistic drug ratios, improving therapeutic efficacy by increasing the percentage of injected dose reaching the tumor. Nonetheless, extravasation-dependent tumor accumulation is susceptible to variations in tumor vasculature; therefore, PLGA-PEG was modified with sulfates to actively target P-selectin–expressing cancers. Here, we show the potential of our platform in unique three-dimensional (3D) in vitro and in vivo models. The P-selectin–targeted nanoparticles showed enhanced accumulation in 3D spheroids and tissues of P-selectin–expressing BRAF-mutated melanomas and BRCA-mutated breast cancers, resulting in superior in vivo efficacy and safety. This nanoplatform could advance the codelivery of a plethora of anticancer drug combinations to various P-selectin–expressing tumors.